Managment of Relapsed/Refractory ALL With Inotuzumab During COVID-19. A Casr Report
We describe the clinical history of a 40-year-old male with relapsed B-common ALL who developed Sars-CoV2 prior to treatment initiation with inotuzumab. Since the patient was asymptomatic for COVID-19, the first dose of inotuzumab was administered, followed by remdesivir as prophylaxis. However, a worsening in respiratory findings led to a delay in administering the following doses of inotuzumab. Interestingly, even if the patient did not receive the full inotuzumab cycle, he achieved a complete hematologic remission: furthermore, he spontaneously developed anti-sars-COV2 antibodies. COVID-19 treatment also included convalescent plasma, leading to negativization of the viral load. The patient, after COVID-19 recovery, received a second full cycle of inotuzumab, underwent allogeneic transplantation, and is currently in complete hematologic and molecular remission, in good clinical conditions, five months from allograft.Keywords:acute lymphoblastic leukemia, COVID-19, inotuzumab, remdesevir, convalescent plasma
Source: Mediterranean Journal of Hematology and Infectious Diseases - Category: Hematology Authors: Martina Di Palma, Elio Gentilini, Chiara Masucci, Alessandra Micozzi, Ombretta Turriziani, Antonino Mul è, Robin Foà, Maurizio Martelli, Gabriella D ' Ettorre, Saveria Capria, Sabina Chiaretti Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Bone Graft | COVID-19 | Hematology | Infectious Diseases | Leukemia | Respiratory Medicine | SARS | Transplants